药械

订阅

MedSci主页 / 所有栏目 / 药械

治疗性前列腺癌疫苗PROSTVAC进入III期研究

2012-04-25 potato 生物谷

新药FDA
关注

*在欧洲，Prostvac是首个进入III期研究的前列腺癌疫苗。 2012年4月17日，据英国每日电讯报，Bavarian Nordic公司治疗性前列腺癌疫苗PROSTVAC已在英国启动了一项III期研究，该研究是PROSPECT试验的一部分，用于研究PROSTVAC在无症状或轻度症状阉割性前列腺癌患者中的治疗作用。 PROSTVAC是基于痘病毒的疫苗，包括了前列腺癌特异性抗原（prostat

*在欧洲，Prostvac是首个进入III期研究的前列腺癌疫苗。

2012年4月17日，据英国每日电讯报，Bavarian Nordic公司治疗性前列腺癌疫苗PROSTVAC已在英国启动了一项III期研究，该研究是PROSPECT试验的一部分，用于研究PROSTVAC在无症状或轻度症状阉割性前列腺癌患者中的治疗作用。

PROSTVAC是基于痘病毒的疫苗，包括了前列腺癌特异性抗原（prostate-specific antigen，PSA）的一段DNA编码序列，在前列腺癌患者中，PSA的水平升高。但Bavarian Nordic公司的疫苗做了小小的改变，能够提高机体的免疫反应。这种疫苗通过皮下注射，每月一次。据每日电讯报，该疫苗是欧洲首个进入III期研究的前列腺癌疫苗。

阉割性前列腺癌（castration-resistant prostate cancer，之前称"激素难治性前列腺癌（hormone refractory）"）的治疗往往只能延长患者仅仅几个月的生命，而且还有副作用。在II期临床试验中，PROSTVAC将患者的生存时间延长了8.5个月。Bavarian Nordic公司总裁Reiner Laus博士告诉每日电讯报，该疫苗的副作用远比现有疗法（如化疗）更加温和，有望在2015年获批。

该项试验在今年1月获得了英国环境、食品和农村事务部（Defra，the Department for Environment, Food and Rural Affairs）的批准，因为它涉及一种经基因改造生物的利用。（生物谷bioon.com）

编译自：FierceVaccine
http://www.fiercevaccines.com/story/dna-vaccine-prostate-cancer-moves-phase-iii/2012-04-17

相关阅读

前列腺癌疫苗Provenge即将投放市场

科学家开发新疫苗有望治愈前列腺癌

Dendreon公司公布前列腺癌疫苗ProvengeⅢ期临床研究初步结果

2011年全球抗肿瘤疫苗研发进展盘点

Astellas的前列腺癌药MDV3100三期研究结果出炉

NIH：并非所有前列腺癌都要急治

10个有前途的治疗性疫苗

治疗性癌症疫苗开创癌症治疗新领域-

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915759, encodeId=c6e61915e595f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jun 19 20:18:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021313, encodeId=8c1a2021313ef, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Feb 12 20:18:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363838, encodeId=cef113638386e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594316, encodeId=e9a715943162c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601663, encodeId=759a16016638d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-06-19 juliusluan78

    #III#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1915759, encodeId=c6e61915e595f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jun 19 20:18:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021313, encodeId=8c1a2021313ef, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Feb 12 20:18:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363838, encodeId=cef113638386e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594316, encodeId=e9a715943162c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601663, encodeId=759a16016638d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2013-02-12 HinsMax

    #III期研究#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1915759, encodeId=c6e61915e595f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jun 19 20:18:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021313, encodeId=8c1a2021313ef, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Feb 12 20:18:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363838, encodeId=cef113638386e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594316, encodeId=e9a715943162c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601663, encodeId=759a16016638d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 lsndxfj

    #ROS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1915759, encodeId=c6e61915e595f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jun 19 20:18:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021313, encodeId=8c1a2021313ef, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Feb 12 20:18:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363838, encodeId=cef113638386e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594316, encodeId=e9a715943162c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601663, encodeId=759a16016638d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 智智灵药

    #III期#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1915759, encodeId=c6e61915e595f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jun 19 20:18:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021313, encodeId=8c1a2021313ef, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Tue Feb 12 20:18:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363838, encodeId=cef113638386e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594316, encodeId=e9a715943162c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601663, encodeId=759a16016638d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 27 02:18:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-04-27 sunylz

    #PRO#

    0

相关资讯

FDA批准抗肿瘤注射液Cisplatin

Strides Arcolab 全资子公司Onco医疗公司的Cisplatin注射液获得美国食品药监局批准。 Cisplatin是一种化疗药,用于治疗包括肉瘤、淋巴瘤和生殖细胞瘤在内的各种癌症。 Cisplatin注射液在50毫升和100毫升的小瓶内的包装是每毫升1毫克。 早在2010年一月份,辉瑞公司曾将Cisplatin在美国上市。 Strides Arcolab公司研发和生产

EpiCept神经痛药物AmiKet获FDA快速审定资格

近日，EpiCept公司的AmiKet获得美国食品药监局（FDA）授予的快速审定资格，这是一种含有4%的阿米替林和2%的氯胺酮的药物。 AmiKet用于治疗由化疗周围神经病变引起的神经痛，这些患者先前都接受过紫杉醇的治疗。 根据FDA的规定，获得快速审定资格的药物会获得有限审定权，比标准的审定时间要缩短大概一半。 EpiCept公司总裁兼首席执行官Jack Talley说：“我们希望通过这次

Neupro贴剂用于治疗帕金森病和不宁腿综合征获FDA批准

2012年4月3日，UCB宣布美国食品药品管理局(FDA)已批准Neupro(罗替戈汀)用于治疗进展期特发性帕金森病(PD)的症状和体征，以及治疗中至重度原发性不宁腿综合征(RLS)。Neupro是一种多巴胺激动剂的透皮贴剂，据称可持续释放药物。 作为一种PD治疗药物，Neupro的作用机制与其对尾壳核内多巴胺受体的刺激作用有关，大脑尾壳核区域具有调节运动的功能。与此相似，对于RLS，Neupr

Idera公司着手银屑病用药IMO-3100II期临床研究

Idera医药公司将开始进行IMO-3100 II期临床研究，这是一种治疗自身免疫疾病（尤其是中重度斑块状银屑病）的铎受体（TLR）抑制剂。 IMO-3100IMO-3100是一种免疫调节剂能够抑制TLR7和TLR9的活性，调节前炎性调节剂的分泌。 设置随机双盲安慰剂控制研究是为了评估IMO-3100单一治疗的药效和安全性。 研究中，将对45名中重度斑块状银屑病患者随机接受IMO-3100或

Inspiration公司向FDA提交IB1001(重组凝血因子IX)生物制品许可申请

2012年4月17日，路透社，Ipsen公司今天宣布，其合作伙伴Inspiration生物制药公司（Inspiration Biopharmaceuticals）已向FDA提交了IB1001的生物制品许可申请（Biologics License Application，BLA），这是一种静脉注射的重组凝血因子IX（fFIX），用于治疗和预防B型血友病患者的出血。 IB1001的BLA包括一项在B

我国治疗性药品地奥心血康胶囊获准欧盟注册上市

4月18日下午，中国科学院在北京人民大会堂举行新闻发布会宣布，其旗下成都地奥制药集团有限公司(地奥集团)自主研制生产的“地奥心血康胶囊”，今年3月下旬以治疗性药品身份通过荷兰药品评价委员会的注册，获得在该国上市许可，实现中国具有自主知识产权治疗性药品进入发达国家主流市场零的突破，同时成为欧盟成员国以外市场准入的第一个植物药。 地奥心血康胶囊是中科院成都生物研究所原所长李伯刚研究员率领团队于198